한국어
English
日本語
中文(简体)Minjuvibju (Tafasitamab)
200mg
Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Tafasitamab is a targeted antibody therapy used for the treatment of non-Hodgkin lymphoma.
MFDS ingredient code M283774
Tafasitamab is a monoclonal antibody that recognizes a specific protein on the surface of cancer cells. It is mainly used to treat blood cancers such as non-Hodgkin lymphoma, targeting cancer cells to induce an immune response.
Tafasitamab binds to specific proteins on the surface of cancer cells, helping immune cells to attack the cancer cells. This suppresses the growth and survival of cancer cells and contributes to the immune system's ability to eliminate cancer cells.
Approved uses differ by product. Check each product's information for its actual use.
Unlike traditional chemotherapy, Tafasitamab is a targeted therapy that leverages the immune system, selectively acting on specific proteins. As a result, it has relatively fewer side effects than conventional chemotherapy and allows for effective treatment.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.